Abstract. Endothelin-1 (ET-1) is a potent vasoconstrictor peptide apparently involved in a number of vascular diseases in man. Nonetheless, its determination in biological samples is difficult, and data on plasma or urine concentrations are controversial. We investigated different sample preparation procedures as well as different radioimmunoassays for their influence on ET-1 measurement. Recovery of ET-1 depended on the extraction procedure, the type and size of the extraction columns and on the biological matrix itself. Incomplete removal of matrix components by the extraction leads to the formation of particulate matter in the evaporated eluate. When dissolved in assay buffer, ET-1 was found to be absorbed to and only partly released from these particulates, so that it was not accessible for measurement in a radioimmunoassay. This was the case for all extraction procedures investigated except for that involving acetic acid. HPLC analysis of spiked samples revealed that ET-1 is in part degraded during extraction, most probably to Meth-sulphoxide ET-1. Dilution curves of synthetic pure ET-1 standards from different suppliers, prepared either in plasma with subsequent extraction or in assay buffer of the respective radioimmunoassay, resulted in considerable differences in the measured values for ET-1-immunoreactivity. Every radioimmunoassay tested had a specific pattern of recognizing different synthetic ET-1 standards. In conclusion, the measurement of ET-1-immunoreactivity is strongly influenced by the experimental conditions of sample preparation as well as by the radioimmunoassay employed.
Introduction
Endothelin-1 (ET-1), which is the most potent vasoconstrictor peptide yet discovered, was originally isolated from culture supernatants of vascular endothelial cells [ 1] . Other mammalian endothelin isopeptides (endothelin-2 and -3) have also been identified, but only ET-1 is produced by endothelial cells and seems to occur in substantial amounts in human plasma. ET-1 is apparently involved in a number of vascular diseases in man. Elevated plasma levels of ET-1 immunoreactivity (ET-1 IR) have been detected in myocardial infarction [2] , vasospastic angina [3] , hypertension [4, 5] , vasculitis [6] , subarachnoid haemorrhage [7, 8] , diabetes mellitus [9, 10] , and HIV infection [11, 12] .
In spite of these numerous studies, data on plasma endothelin concentrations are hardly comparable and in part controversial [9, 10, [13] [14] [15] [16] . Although several radioimmunoassays (RIA) for the selective measurement of ET-1 are available, results from different laboratories vary considerably. There is no consensus technique for the determination of this peptide, nor is there a generally accepted normal range in human plasma [9, 13] . Moreover, the antisera used in the respective RIAs are sensitive to small modifications in the chemical structure of ET-1, as shown by the (often considerable) cross-reactivity of antisera between the three different but structurally closely related endothelins.
ET-1 cannot be measured directly in biological fluids, but must be purified and concentrated by an extraction step. The chemical structure of this 21-amino-acid peptide includes two intrachain disulphide bonds (between positions 1-15 and 3-11) as well as one methionine in position 7 [1]. Therefore, it is very susceptible to chemical modification; reduction with subsequent cleavage of the disulphide bonds as well as oxidation of the methionine may occur during storage or processing of samples, depending on the assay conditions. Very little is known of the influence of these degradation products on the binding affinity of ET-1 to the antibodies used in the respective radioimmunoassays. Moreover, matrix components like proteins, lipids, or salts not removed by the extraction procedure may influence the binding of the antibodies to ET-1 in a given radioimmunoassay. The purpose of this study, therefore, was to evaluate several extraction procedures described in terms of recovery and stability of ET-1, and to investigate several available RIAs regarding the immunoreactivity of different synthetic ET-1 preparations in order to establish a reliable method for the determination of ET-1 in biological fluids.
Materials and methods

Reagents
Synthetic purified ET-1 was obtained from several suppliers: Serva (Heidelberg, Germany), Sigma (Deisenhofen, Germany), Peninsula (Belmont, Calif.) and NEN/Dupont (Dreieich, Germany). Synthetic ET-2 and ET-3 were purchased from Serva and 3-[1251] iodotyrosyl ET-1 with a specific activity of 74 TBq/mmol and a radiochemical purity of > 90% from Amersham (Braunschweig, Germany).
Extraction was performed on silica-C 18 cartridges (Sepak C 18 Vac, 500 mg, Waters/Millipore, Eschborn, Germany) unless otherwise indicated. Other extraction cartridges tested were Sepak C 18 classic 360 mg (Waters/Millipore) and Bond-Elut S i-C 18 500 mg, 200 rag, 100 mg (Analytichem International, obtained from ict, Frankfurt, Germany). Columns were used only once.
